^
    Back
    Association details:
    Biomarker:PBRM1 mutation
    Cancer:Biliary Tract Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO-GI 2023
    Title:

    P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice

    Published date:
    06/27/2023
    Excerpt:
    From the genetic point of view, a statistically significant difference in terms of prevalence of PBRM1 mutation was highlighted between responders and non-responders, since a higher prevalence of PBRM1 mutated patients was observed in the responders’ group compared to nonresponders’ group (31% Vs 6.5%)....The present work reported the first genomic analysis on a cohort of patients who received cisplatin/gemcitabine plus durvalumab as first-line treatment in a real-world setting.
    Secondary therapy:
    cisplatin + gemcitabine
    DOI:
    10.1016/j.annonc.2023.04.399